Loading company…
Renjing Biology develops mRNA-based drugs, with a focus on therapeutic oncology vaccines.
Renjing Biology researches and develops mRNA-based drugs and provides clinical research, drug development, and GMP production services. Its pipeline focuses on therapeutic oncology vaccines, supported by platforms for linear mRNA, circular mRNA, and targeted LNP delivery. Founded in 2021, the company is based in Suzhou, China, and is at Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in